Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals

Product Overview

Selcaxen 40 mg Capsule by Everest Pharmaceuticals Ltd., Bangladesh contains Selpercatinib. It is listed here as a same-ingredient branded option for people researching Retevmo / Retsevmo, a reference brand associated with Eli Lilly. Selcaxen and Retevmo / Retsevmo must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 40 mg strength.

Selcaxen vs. Retevmo / Retsevmo – Originator / Reference Brand Comparison

Retevmo / Retsevmo is a widely recognized reference brand for Selpercatinib associated with Eli Lilly. Selcaxen is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Selcaxen is manufactured by Eli Lilly, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.

Composition and Active Ingredient

Active ingredient: Selpercatinib
Strength: 40 mg
Dosage form: Capsule
Pharmacological class: RET inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.

Therapeutic Uses and Indications

Selpercatinib is used in selected RET-altered lung or thyroid cancers. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.

Mechanism of Action – How Selpercatinib Works

Selpercatinib is a RET inhibitor. In general, it selectively inhibits RET kinase signaling. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.

Dosage and Administration

The product contains 40 mg per capsule; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.

Contraindications

Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.

Warnings and Precautions

Important precautions for Selpercatinib include: high blood pressure, liver injury and QT prolongation. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.

Possible Side Effects

The adverse-effect profile of Selpercatinib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include high blood pressure, liver injury and QT prolongation. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.

Drug Interactions

Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Selpercatinib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.

Pregnancy, Fertility and Breastfeeding

Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Selpercatinib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.

Storage and Handling

Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.

Why Is Selcaxen Listed as an Alternative to Retevmo / Retsevmo?

This listing helps customers identify an Everest Pharmaceuticals product containing Selpercatinib while researching Retevmo / Retsevmo. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.

Manufacturer Information

Listed brand: Selcaxen
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Retevmo / Retsevmo
Reference company: Eli Lilly
Generic ingredient: Selpercatinib
Strength: 40 mg
Dosage form: Capsule
Therapeutic class: RET inhibitor

Frequently Asked Questions

What is Selcaxen 40 mg?

It is an Everest Pharmaceuticals capsule containing Selpercatinib 40 mg.

Is Selcaxen the same as Retevmo / Retsevmo?

They are presented as brands associated with Selpercatinib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.

What is Selpercatinib used for?

Selpercatinib is used in selected RET-altered lung or thyroid cancers, subject to the applicable label and clinical assessment.

How does Selpercatinib work?

It selectively inhibits RET kinase signaling.

Can I switch strengths or brands myself?

No. A licensed prescriber or pharmacist must assess any substitution.

Is a prescription needed?

Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.

Important Medical Disclaimer

This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.